{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:13Z","timestamp":1791414133295,"version":"4.3.3"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:italic>Bacillus anthracis<\/jats:italic>\n            , the causative agent of anthrax, can produce fatal disease when it is inhaled or ingested by humans. Dalbavancin, a novel, semisynthetic lipoglycopeptide, has potent activity, greater than that of vancomycin, against Gram-positive bacteria and a half-life in humans that supports once-weekly dosing. Dalbavancin demonstrated potent\n            <jats:italic>in vitro<\/jats:italic>\n            activity against\n            <jats:italic>B. anthracis<\/jats:italic>\n            (MIC range, \u22640.03 to 0.5 mg\/liter; MIC\n            <jats:sub>50<\/jats:sub>\n            and MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.06 and 0.25 mg\/liter, respectively), which led us to test its efficacy in a murine inhalation anthrax model. The peak concentrations of dalbavancin in mouse plasma after the administration of single intraperitoneal doses of 5 and 20 mg\/kg of body weight were 15 and 71 mg\/kg, respectively. At 20 mg\/kg, the dalbavancin activity was detectable for 6 days after administration (terminal half-life, 53 h), indicating that long intervals between doses were feasible. The mice were challenged with 50 to 100 times the median lethal dose of the Ames strain of\n            <jats:italic>B. anthracis<\/jats:italic>\n            , an inoculum that kills untreated animals within 4 days. The efficacy of dalbavancin was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg\/kg every 36 h (q36h) or 30 to 240 mg\/kg every 72 h (q72h). A regimen of ciprofloxacin known to protect 100% of animals was tested in parallel. Delayed dalbavancin treatment (beginning 36 or 48 h postchallenge) with 60 mg\/kg q36h or 120 mg\/kg q72h still provided 70 to 100% survival. The low MICs and long duration of efficacy\n            <jats:italic>in vivo<\/jats:italic>\n            suggest that dalbavancin may have potential as an alternative treatment or for the prophylaxis of\n            <jats:italic>B. anthracis<\/jats:italic>\n            infections.\n          <\/jats:p>","DOI":"10.1128\/aac.00820-09","type":"journal-article","created":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T02:10:30Z","timestamp":1262657430000},"page":"991-996","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Activity of Dalbavancin against\n            <i>Bacillus anthracis In Vitro<\/i>\n            and in a Mouse Inhalation Anthrax Model"],"prefix":"10.1128","volume":"54","author":[{"given":"Henry S.","family":"Heine","sequence":"first","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret K.","family":"Purcell","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bassett","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Miller","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth P.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Vicuron Pharmaceuticals, a wholly owned subsidiary of Pfizer, Inc., New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-07"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01264-06"},{"key":"e_1_3_2_4_2","first-page":"306","volume":"340","year":"1992","unstructured":"Bradaric, N., and V. Punda-Polic. 1992. Cutaneous anthrax due to penicillin-resistant Bacillus anthracis transmitted by an insect bite. Lancet340:306-307.","journal-title":"Lancet"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00464-2"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005280378"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki006"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2307-2309.2002"},{"key":"e_1_3_2_9_2","first-page":"889","volume":"50","year":"2001","unstructured":"CDC. 2001. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines. MMWR Morb. Mortal. Wkly. Rep.50:889-897.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_10_2","first-page":"909","volume":"50","year":"2001","unstructured":"CDC. 2001. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy. MMWR Morb. Mortal. Wkly. Rep.50:909-919.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1766-1766.2000"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"CLSI document M7-A7. 2006","DOI":"10.1201\/9781420006360.ax7"},{"key":"e_1_3_2_13_2","unstructured":"CLSI document M100-S18. 2008"},{"key":"e_1_3_2_14_2","first-page":"206","volume":"50","year":"2004","unstructured":"Darouiche, R. O., and D. M. Mansouri. 2004. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in an animal model. J. Infect.50:206-209.","journal-title":"J. Infect."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5099-5106.2005"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365549109024319"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki008"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008321273"},{"key":"e_1_3_2_19_2","first-page":"335","volume":"20","year":"2000","unstructured":"Friedlander, A. M. 2000. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr. Clin. Top. Infect. Dis.20:335-349.","journal-title":"Curr. Clin. Top. Infect. Dis."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1239"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1955.00250140109012"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00620-06"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1968-1971.2003"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00286-06"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-06"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00360-08"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2236"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1118-1123.2004"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/497271"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.6.593"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.08.015"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.182.10.2928-2936.2000"},{"key":"e_1_3_2_33_2","first-page":"77","year":"2006","unstructured":"Leffel, E. K., and L. M. Pitt. 2006. Anthrax, p. 77-94. In J. R. Swearengen (ed.), Biodefense. Research methodology and animal models. CRC Press, Boca Raton, FL.","journal-title":"Biodefense."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.1061-1064.2004"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.940-945.2004"},{"key":"e_1_3_2_36_2","first-page":"95","volume":"68","year":"1990","unstructured":"Lightfoot, N. F., R. J. D. Scott, and P. C. B. Turnbull. 1990. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med. Bull.68(Suppl.):95-98.","journal-title":"Salisbury Med. Bull."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.770-772.2005"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5182-5184.2005"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01875-06"},{"key":"e_1_3_2_40_2","unstructured":"Guide for the care and use of laboratory animals. 1996"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm263"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.5.429"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2362-2365.2003"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1086\/427283"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.09.004"},{"key":"e_1_3_2_46_2","first-page":"37988","volume":"67","year":"2002","unstructured":"U.S. Food and Drug Administration. 2002. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed. Regist.67:37988-37998.","journal-title":"Final rule. Fed. Regist."},{"key":"e_1_3_2_47_2","unstructured":"Draft guidance for industry inhalational anthrax (post-exposure)\u2014development of antimicrobial drugs. 2002"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00820-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00820-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:23:39Z","timestamp":1645475019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00820-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1128\/AAC.00820-09"],"URL":"https:\/\/doi.org\/10.1128\/aac.00820-09","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"2009-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-12-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}